Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo

Journal of Steroid Biochemistry and Molecular Biology

Volumn 116, Issue 3-5, 2009, Pages 121-126

  Ries, Christina ^a   Lucas, Simon ^a   Heim, Ralf ^a   Birk, Barbara ^b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

Author keywords

Aldosterone; Heart failure; Inhibitor screening; Myocardial fibrosis; Plasma aldosterone level; Rat CYP11B2

Indexed keywords

3,4 DIHYDRO 1H QUINOLIN 2 ONE DERIVATIVE; ALDOSTERONE; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; CORTICOTROPIN; ENZYME INHIBITOR; FADROZOLE; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR CLONING; NONHUMAN; PLASMID; RAT; SCREENING;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; QUINOLONES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 67650690564     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.04.013     Document Type: Article

References (25)

1. Kawamoto T., Mitsuuchi Y., Toda K., Yokoyama Y., Miyahara K., Miura S., Ohnishi T., Ichikawa Y., Nakao K., Imura H., Ulick S., and Shizuta Y. Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 1458-1462
2. Davila D.F., Nunez T.J., Odreman R., and de Davila C.A. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int. J. Cardiol. 101 (2005) 343-346
3. Brilla C.G. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc. Res. 47 (2000) 1-3
4. Lijnen P., and Petrov V. Induction of cardiac fibrosis by aldosterone. J. Mol. Cell. Cardiol. 32 (2000) 865-879
5. Sato A., and Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 29 (2001) 13-21
6. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341 (1999) 709-717
7. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003) 1309-1321
8. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., and Redelmeier D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351 (2004) 543-551
9. Ménard J., Gonzalez M.-F., Guyene T.-T., and Bissery A. Investigation of aldosterone-synthase inhibition in rats. J. Hypertens. 24 (2006) 1147-1155
10. Hartmann R.W. Selective inhibition of steroidogenic P450 enzymes: current status and future perspectives. Eur. J. Pharm. Sci. 2 (1994) 15-16
11. Ulmschneider S., Müller-Vieira U., Klein C.D., Antes I., Lengauer T., and Hartmann R.W. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 48 (2005) 1563-1575
12. Ulmschneider S., Müller-Vieira U., Mitrenga M., Hartmann R.W., Oberwinkler-Marchais S., Klein C.D., Bureik M., Bernhardt R., Antes I., and Lengauer T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J. Med. Chem. 48 (2005) 1796-1805
13. Voets M., Antes I., Scherer C., Müller-Vieira U., Biemel K., Barrasin C., Oberwinkler-Marchais S., and Hartmann R.W. Heteroaryl substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 48 (2005) 6632-6642
14. Voets M., Antes I., Scherer C., Müller-Vieira U., Biemel K., Oberwinkler-Marchais S., and Hartmann R.W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 49 (2006) 2222-2231
15. Ehmer P.B., Bureik M., Bernhardt R., Müller U., and Hartmann R.W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid. Biochem. Mol. Biol. 81 (2002) 173-179
16. Hartmann R.W., Müller U., and Ehmer P.B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur. J. Med. Chem. 38 (2003) 363-366
17. Müller-Vieira U., Angotti M., and Hartmann R.W. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11β-hydroxylase) inhibitors. J. Steroid. Biochem. Mol. Biol. 96 (2005) 259-270
18. Heim R., Lucas S., Grombein C.M., Ries C., Schewe K.E., Negri M., Müller-Vieira U., Birk B., and Hartmann R.W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. J. Med. Chem. 51 (2008) 5064-5074
19. Lucas S., Heim R., Negri M., Antes I., Ries C., Schewe K.E., Bisi A., Gobbi S., and Hartmann R.W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J. Med. Chem. 51 (2008) 6138-6149
20. Lucas S., Heim R., Ries C., Schewe K.E., Birk B., and Hartmann R.W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J. Med. Chem. 51 (2008) 8077-8087
21. Imai M., Shimada H., Okada Y., Matsushima-Hibiya Y., Ogishima T., and Ishimura Y. Molecular cloning of a cDNA encoding aldosterone synthase cytochrome P-450 in rat adrenal cortex. FEBS Lett. 263 (1990) 299-302
22. Swedberg K., Eneroth Q., Kjekshus J., Wilhelmsen L., and CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1736
23. Tsuji H., Venditti Jr. F.J., Evans J.C., Larson M.G., and Levy D. The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am. J. Cardiol. 74 (1994) 232-235
24. Anand K., Mooss A.N., and Mohiuddin S.M. Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. J. Renin Angiotensin Aldosterone Syst. 7 (2006) 15-19
25. Robert V., Silvestre J.-S., Charlemagne D., Sabri A., Trouvé P., Wassef M., Swynghedauw B., and Delcayre C. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26 (1995) 971-978